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 Abstract 
Metabolic syndrome (MetS) is commonly presumed to stem from obesity, with both propelled 
by energy surfeit: positive balance of calories consumed to energy expended. A complementary 
thesis is proposed: that episodes of cell energy deficit (not expressly calorie deficit) drive MetS – 
the “Starving Cell.”  
Risk factors for MetS include hypoxemia from sleep apnea, severe calorie debt, mitochondrial 
dysfunction, oxidative stress; and sleep restriction, illness, surgery, trauma, cold. Each fosters 
inadequate cell energy, hampering production or boosting demand. MetS factors support energy: 
glucose, triglycerides, abdominal/visceral fat – and blood pressure, sustaining perfusion. 
Additional energy-supportive adaptations co-occur in MetS: e.g. increased free fatty acids and 
deposition of metabolically active ectopic fat. Indeed, increased appetite/calories and reduced 
activity – features of the energy surfeit model – also arise as adaptations to cell energy 
deprivation. Among persons who are overweight, the risk for MetS remains determined by 
energy deprivation contributors.  
The Thrifty Gene hypothesis, and MetS promotion by fetal energy deprivation, prefigure the 
Starving Cell thesis. However, evidence is vastly more comprehensive in connecting cell energy 
deprivations to MetS elements: generalizing the sources of energy deficit that dispose to MetS; 
the populations vulnerable to their impact; and the forms of adaptation implemented to protect 
energy. This clarifies why MetS factors cohere; and why other energy-supportive adaptations 
attend them. It explains bidirectional MetS associations; and why MetS factors appear 
“paradoxically” protective in some populations. It generates predictions, and suggests 
approaches to MetS mitigation that complement and modify existing approaches, and may 
augment their efficacy.
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 Introduction 
Metabolic syndrome (MetS) is Epidemic.  Is this the result of cell Energy Surfeit as commonly 
supposed?  Or might cell Energy Deficit “paradoxically” play a role? 
Metabolic syndrome (MetS) has been termed the “epidemic of the XXI century”1. Its prevalence 
is exploding, not just in overfed developed nations but worldwide2-11. With its attendant risks of 
diabetes mellitus (DM)12, heart disease2,12-15, stroke15,16, depression17, functional decline18, 
cancer19-21 and all-cause mortality12, the devastating toll from the rising MetS-obesity epidemic 
is projected to drive skyrocketing healthcare costs22 and reversal of gains in longevity23.   
 
To effectively tackle the rise in MetS, we must first understand it. The current understanding of 
MetS often focuses on energy surfeit – too many calories in, too few expended, excess calories 
deposited as fat, MetS arising in consequence–but this leaves many questions unanswered. Why 
do the seemingly disparate features that are aggregated as “MetS” cohere? Why do factors 
ranging from sleep apnea to sleep deprivation to skipped meals to winter months promote MetS? 
Why is MetS linked bidirectionally to some factors, like sleep duration (both long and short sleep 
being linked)? What accounts for the relation to diverse markers like uric acid, GGT, CRP and 
fibrinogen? Why is MetS linked to outcomes ranging from depression to cancer? Why does 
“correcting” one MetS factor not infrequently occasion worsening in another? Why do MetS 
features bear protective rather than adverse associations to mortality in some populations? And 
what unites these populations?   
 
This paper suggests what may seem a radical rethinking of MetS, in which one simple construct–
the Starving Cell–provides a coherent framework within which these findings are explained. 
Energy is central to survival. Again and again, risk factors for MetS are those that foster periods 
of cell energy deficit: they impede energy production or increase energy demand. And MetS 
factors “cohere” in that each supports cell energy. Moreover, an array of other energy protections 
rise in concert with MetS–e.g. free fatty acids, and metabolically active ectopic fat.  
 
Although the ideas proposed may initially seem counterintuitive, they are not entirely without 
precedent. In the Thrifty Gene hypothesis, caloric restriction and energetic challenges in prior 
generations are theorized to increase risk of obesity in future ones, when calorie access is 
restored. Additionally, fetal energy deprivation has been recognized to promote MetS24,25. These 
each prefigure the Starving Cell thesis. However, the Starving Cell perspective, as will become 
clear, has far broader reach in connecting cell energy deprivations to MetS elements. It expands 
the sources of energy deficit that dispose to MetS; generalizes the populations vulnerable to their 
impact; and broadens the forms of adaptation implemented to protect energy. Each of the claims 
is supported by empirical evidence. 
 
It is reasonable to be skeptical that cell energy deficit may bear blame, since for many with 
MetS, food calories are abundant. This is unquestionably true, but 1. Food calories do not alone 
determine cell energy production. (We are, after all, aerobic organisms!) Numerous secular 
shifts–increased exposure to oxidative stressors, mitochondrial toxins, micronutrient depleted 
foods, and altered eating patterns, as well as sleep apnea–contribute to periods of cell energy 
risk. Many lines of evidence are shown that support the thesis that periods of energetic deficit 
serve to increase energetic adaptations, both including MetS factors (glucose levels, triglyceride 
levels, fat deposition, blood pressure to ensure delivery of substrates), and extending beyond 
them. 2. Moreover, it is not supposed that surplus calories are irrelevant to weight gain: To the 
contrary, it is suggested that episodes of unmet energetic needs may both increase the 
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physiological drive to consume surplus calories, and increase the drive for surplus calories (when 
present) to be deposited as fat–while concurrently promoting other elements of MetS. (The 
excess fat itself may then propel further episodes of energetic deficit.∇) MetS features, it is 
proposed, serve adaptive functions when the next energetic challenge arises. Though at first 
glance the concept of the Starving Cell may seem counterintuitive, once the evidence is fully 
assembled, it may transition from far-fetched to self-evident. It explains numerous observations 
that are otherwise enigmatic. It is predictive. And it offers strategies to arrest the epidemic of 
MetS that variably reinforce, complement, and depart from, current approaches. 
 
The Features of MetS Serve to Support Cell Energy 
MetS elements include elevated blood pressure (BP), abdominal girth, triglycerides (with low 
high density lipoprotein cholesterol or HDL), and serum glucose26. Each is statistically 
associated with increased likelihood of the others. DM arises when elevated serum glucose 
exceeds a stipulated threshold, and it is not uncommonly accompanied by other MetS elements. 
In the discussion to follow, statements referring to MetS generally apply, in addition, to DM 
(which is used here to refer to type II diabetes specifically). Since the epidemic of obesity and 
that of MetS and DM are clearly linked5, a common view is that all arise as a consequence of a 
cell energy surfeit: When too many calories are consumed, and too few calories expended, the 
excess calories are deposited as fat, producing weight gain which then, according to this view, 
drives insulin resistance (IR) and MetS4,27,28–and DM. “When energy balance is positive, weight 
increases”29 with MetS as a presumed consequence. Indeed, this may be true to an extent (as the 
first footnote suggests). But it cannot explain why it is that MetS is increasingly being seen to 
extend beyond affluent societies with ample calorie access, to poor and developing nations30, and 
to persons without obesity31. In fact, numerous findings fail to fit the energy surfeit model. 
 
Energy deprivations have previously been noted to promote MetS in circumscribed settings 
The Starving Cell perspective is presaged by the “thrifty gene hypothesis,” which relates the 
impact of low calorie access in earlier generations to risk of obesity and MetS in later ones, in 
whom calorie access is restored–and calorie composition is modified. It is further prefigured by 
findings regarding underweight fetuses, that relate the impact of growth retardation or low access 
to calories or energy sources in fetal life to risk of obesity and MetS and its components and 
accompaniments in later life32, extending to adulthood24,33,34–when calorie access is not 
restricted. But evidence, it will be shown, supports a perspective that is more comprehensive in 
connecting energy deprivation to MetS and its elements. This perspective, the Starving Cell 
hypothesis, broadens the sources of cell energy deficit (beyond calorie deprivation) that dispose 
to MetS, expands the forms of adaptation implemented to protect against them, and extends the 
populations susceptible to their impact.  
 
The Starving Cell – and Evidence 
We will review the evidence that underlies this proposition: that MetS elements, the central 
weight gain that can accompany (and contribute to) them, and the DM that can emanate in 
relation to MetS elements, are promoted by episodes of cell energy deficit. These episodes drive 
adaptive mechanisms that foster a rise in accessory sources of cell energy–such as glucose, 
triglycerides, and visceral fat – i.e. MetS factors; and seek to ensure against hypoperfusion–and 
                                                 
∇
  For instance, in an energy impoverished milieu, an equivalent level of overweight is more likely to foster 
nocturnal hypoxemia – as the greater workload of recumbent breathing is superimposed on preweakened airway and 
respiratory muscles. Moreover, for the same level of hypoxemia, a greater degree of cell energy compromise will 
ensue where factors already adversely affecting cell energy supply-demand balance are present. 
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resulting loss of access to oxygen, glucose, triglycerides, and free fatty acids in underperfused 
areas–via increased blood pressure. We will review the evidence that MetS factors are merely the 
most routinely tested elements among a range of adaptive changes to support energy supply and 
limit energy demand, with ectopic and visceral fat, free fatty acids, and other sources co-
occurring35.   
 
Secular Trends Motivating the Energy Surfeit View are Not Disputed. There are indeed secular 
trends that provide for more access to food calories; and less exercise undertaken to expend 
them–concurrent with, and contributing to, the epidemic of obesity. Many modern efficiencies 
reduce the need for energy expenditure. Examples range from indoor plumbing to automotive 
transportation, washing machines to preprepared comestibles. In addition to reductions in 
“obligatory” energy expenditures, many impediments hamper spontaneous discretionary energy 
expenditure. These include smaller yards and fewer local safe open spaces for play and activity, 
coupled with an increased premium on safety and a litigious society. Greater population density 
imposes new real and perceived threats restricting unsupervised play. Television and computers 
have become popular leisure time “activities.” Additionally, large segments of the population 
have ready access to food. These are among many factors that indeed foster a positive time-
averaged balance of food calories ingested relative to activity calories expended. The resulting 
energy surfeit has been a primary focus of efforts to explain and address MetS.   
And energy surfeit is not presumed inherently irrelevant to MetS; indeed, signals fostering 
increased appetite and fatigue (reduced activity) are among the demonstrated adaptive 
modifications that arise in some settings of energy deficit. And it is acknowledged that increased 
feeding and reduced activity contribute to weight gain, and may exert MetS influence whether or 
not adaptively provoked. However, here it is proposed that the risk of MetS is amplified–and 
even engendered–by conceptual considerations that complement periods of calorie surfeit – 
promoting these periods, and magnifying their impact.  
 
Nor is it disputed that changes in diet and exercise play a role; but the understanding of how they 
do so is modified. Exercise deficit may serve as a risk factor not expressly by promoting energy 
excess, but by promoting energy deprivation (especially in the longer term), by means reviewed 
below. And it is suggested that it is not only the number of food calories that matters (promoting 
calorie surfeit), but the shift in the character of the individual foods and the pattern with which 
they are eaten (promoting energy deficit) that bear blame – and perhaps even primary blame. 
When the calories that are consumed do not serve the intended goal of yielding adequate cell 
energy production for healthy cell function, then the drive for consuming calories may not abate; 
and/or needed energy supports–MetS factors and their brethren–may be implemented.  
 
Cell energy is critical to survival – and demands adaptive mechanisms. Many perils that are 
linked to MetS and often presumed to be “caused by” MetS, may follow instead from the energy 
threat that occasioned the MetS, and from the sources of this energy threat - such as oxidative 
stress or inadequacy of certain nutrients. But MetS factors themselves pose perils. For instance, 
very high blood pressure may conduce to stroke (presumably beyond the energy demand that 
produced the very high blood pressure); very high blood glucose can cause damage through 
glycation endproducts; very high weight places demands on joints and slows movement. To 
understand why factors like those comprising MetS may arise as evolutionary adaptations, 
despite the potential for producing problems of their own, it is essential to acknowledge the 
degree to which adequate cell energy is critical to survival of the cell; and the function of the 
cell. Proper function of cells is in turn critical to survival of the organism, i.e., the person. Heart, 
brain, and muscle are powerfully energy demanding organs–and these and other organs must 
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work properly if one is to evade predators and enemies, and survive the gauntlet of infections, 
injuries and challenges in an often treacherous natural world (through much of evolution). 
Energy is essential, too, if one is to procreate. Because of how very central energy is to organism 
survival and reproduction, there is a powerful impetus for evolutionary development of adaptive 
mechanisms to protect cell access to energy should problems arise with energy supply–or, more 
accurately, with energy supply-demand balance. 
 
Even brief periods of marked cell energy inadequacy can damage cell function and viability. 
This is attested by the short time to death if one stops breathing: minutes, in humans. Periods of 
less extreme cell energy deficit may threaten cell function and viability, particularly when 
repeated. Evidence clearly shows cell function can be lost even when energy deprivation falls 
short of producing cell lethality. Recognized instances, in energy demanding tissues, include 
hibernating myocardium17 and idling neurons36,37. Cell energy support in these settings is pivotal 
to restoring these cells to serving as capable contributors (vs. dysfunctional drains on cell 
resources), and protecting against cell death. This context makes sense of many observations, 
such as the well-known finding that normalizing high blood pressure after stroke is in fact 
harmful–adequate blood and oxygen to areas with marginal perfusion is essential to prospects to 
rescue cells that have been, let us say stunned, but are not yet dead. Indeed, blood pressure 
raising therapy following stroke has been shown to reduce stroke expansion38,39–a less widely 
known finding.  
 
This case illustrates a more general principle: MetS factors have repeatedly portended better 
rather than worse outcomes in a range of settings in which energy supply-demand balance is 
unfavorable (described below). These findings have generally been viewed as perplexing, but are 
rendered intuitive under the Starving Cell perspective. In samples including many healthy 
individuals, presence of MetS factors serve as signatures of (periods of) energy deficit and 
challenges relating to this – and periods of energy deficit may persist even if MetS adaptations 
have been implemented in an effort to offset these. In part or substantially through this means, 
MetS factors in this setting may portend more adverse outcomes. In contrast, in studies of 
persons affected by conditions characterized by energetic adversity (such as heart failure, 
wasting disease, or old age with its attendant loss of mitochondrial function), absence of MetS 
factors may signal failure to implement successful adaptations, so that presence of MetS factors 
may show neutral or even favorable relations of MetS factors to mortality in these settings. 
 
Energy balance depends on many factors beyond calorie intake relative to expenditure.  
The term “Starving Cell” may seem particularly counterintuitive unless it is understood, as 
intended, to mean the cell is starved for energy, not expressly for dietary calories. Even where 
dietary calories are plentiful, cell energy can be inadequate.  
 
Adequate cell energy production requires oxygen, vital capacity, red blood cells to transport 
oxygen, blood volume and adequate blood pressure to carry it even through small compromised 
capillaries (so salt and water), blood vessel patency (so good endothelial function and limited 
atherosclerosis), good function of mitochondria to generate energy from substrates, nutrients to 
allow cellular machinery to perform the legion functions required for energy production (such as 
micronutrient, energy substrate, and cofactor assimilation and delivery, transport of mitochondria 
in microtubules, mitochondrial protein production and function), adequate antioxidant support to 
the level of oxidative stress challenges (since oxidative stress compromises mitochondrial 
function and endothelial function, providing at least dual damage to energetics), sustained 
acceptable levels of glucose, adequate accessory energy sources to meet demands–and/or energy 
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demands not in excess of energy sources, and preferably some exercise (to support mitochondrial 
number, antioxidant status, venous return, and good cardiac and respiratory muscle function–to 
draw in and deliver oxygen and nutrients, and effectively convert them to energy)40. And indeed, 
compromise to any of these energy-important elements is empirically linked to risk of MetS. 
 
MetS risk rises in multiple settings of reduced energy production 
Efficient mitochondrial function is central to efficient ATP production41. Mitochondrial 
efficiency is adversely affected by any of a range of mitochondrial DNA mutations, particularly 
with higher “heteroplasmy”–i.e. fraction of mitochondrial DNA that are mutated, via one or 
multiple mutations (“microheteroplasmy”42). If cell energy surfeit were the source of MetS, 
mitochondrial defects and dysfunction should each reduce the risk of MetS. Yet antithetical to 
the energy surfeit view, and consistent with the Starving Cell perspective, mitochondrial defects 
and dysfunction–classically impairing cell energy production–have repeatedly been linked to 
MetS, and each MetS element43-52. Conversely, supplementation with coenzyme Q10, supporting 
mitochondrial electron transport and energy production, has been found in some studies to 
improve each of the MetS elements17. Supplementation with coenzyme Q10 has been reported to 
partially bypass many mitochondrial respiratory chain defects53-56 and Q10 is also a major 
endogenous lipophilic antioxidant57,58 (and increases levels of other mitochondrially relevant 
antioxidants, as well as recycling them to the reduced form59-63), benefiting deficient 
mitochondrial energy production by these means. A particularly intriguing finding has been 
reported in children with Praeder Willi syndrome, a genetic condition entailing generalized 
fatigue (itself an energy supportive adaptation, reducing energy demand), prolonged sleep hours 
(an energy supportive adaptation) and starvation feeding behaviors (an energy supportive 
adaptation). Affected individuals will go to extremes to get access to food and are generally 
obese. In children with this condition, coenzyme Q10 supplementation was reported to arrest 
starvation feeding behaviors and reduce prolonged sleep hours, a benefit that reversed with Q10 
withdrawal64. Somatic mitochondrial DNA mutations increase with age and oxidative stress 
exposure42,65,66–mutating, indeed, 10-1000 times more than nuclear DNA67-69, and the Starving 
Cell perspective suggests that this observation is not irrelevant to the powerful association of 
age2,70-73, and of oxidative stress to increased risk of MetS74,75–rather than MetS protection, as 
the energy surfeit perspective would suggest. Moreover drugs with mitochondrial toxicity have 
been linked to MetS risk76-80.  
 
Cell energy production requires a wide range of supportive nutrients and cofactors essential to 
cell function, particularly but not exclusively to mitochondrial function. Nutrient deficiencies 
have been repeatedly linked to MetS and its factors81, while diets rich in micronutrients (e.g. the 
DASH diet high in fruits, vegetables and dairy, and Mediterranean style diets–or 
supplementation with vitamin D, which bears a role in energy production) reduce multiple 
elements of MetS82-88. Additional citations for these points are included in Table 1 and footnotes. 
It is sometimes difficult, however, to divorce these findings completely from antioxidant 
protections that attend many of the micronutrient-rich products found to be relevant. 
 
Oxidative stress has been centrally linked to MetS74,75,89-94, so much so that some have deemed it 
a “novel component” of MetS89 or deemed oxidative stress to provide a unifying hypothesis for 
MetS74. (Here, it is subsumed as one contributor in a larger unifying construct.) Cell energy 
requires a favorable antioxidant to oxidative stress balance. This is because oxidative stress 
impairs both endothelial function95-98 (needed for adequate vessel caliber and bloodflow in 
response to need, enabling delivery of oxygen, energy substrates and cofactors) and 
mitochondrial function99-101. Mitochondria are the major target (as well as source) of reactive 
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oxygen species (ROS)99,102. ROS adversely affect mitochondrial proteins, DNA, RNA and 
lipids99,103, compromising mitochondrial production of energy99 and also leading in turn to still 
further mitochondrial ROS production101,102. Therefore effective energy production requires 
ample antioxidant protections to guard mitochondrial machinery against oxidative damage99,104, 
and/or limited exposure to oxidative stressors. A less favorable balance of antioxidant defense to 
oxidative stress will more greatly dispose to energy impairment–and MetS. 
 
A range of oxidative stressors, extending to drugs that promote oxidative stress78,79,105, have been 
linked to MetS and its elements93,106. The Starving Cell thesis predicts that numerous others, 
when assessed, will be found to promote MetS as well. Conversely diets rich in antioxidants and 
micronutrients107 (and antioxidant rich products such as coffee, chocolate, fruits, vegetables, 
nuts, and coenzyme Q10), preserving cell and energetic function108-110, have been linked to lower 
MetS risk83,111-114. Meanwhile, deficiencies in serum and tissue antioxidants and nutrients have 
been presumptively linked to increased MetS risk115-122. (See Table 1, including footnote 
comment on oxidative preconditioning123,124.) According to the energy surfeit view, antioxidants, 
via support of cell energetics, should promote MetS. However, favorable antioxidant:prooxidant 
status has been linked to better status of MetS factors, while oxidative stress has been linked to 
risk. 
 
Cell energy adequacy requires consistent access to key substrates for energy production.  
Thus, it requires that neither oxygen nor blood glucose levels dip too much or too often, 
compromising cell function and viability. It requires that access of cells to blood be adequate 
consistently, since blood transports oxygen, glucose (and other energy substrates), micronutrients 
required for cellular machinery, and antioxidants. Particularly for relatively hypoperfused areas–
e.g. fed by small capillaries or vessels with atherosclerotic blockage–adequate tissue perfusion 
requires that blood volume and blood pressure are adequate. It also requires good endothelial 
function, allowing blood/oxygen redistribution to tissues in need–again requiring a favorable 
balance of antioxidant defenses to oxidative stressors (since oxidative stress is a key contributor 
to endothelial dysfunction)95-98. Again, compromise to these needs would be predicted to reduce 
MetS according to the energy surfeit view.  
 
Rather, even intermittent compromise to oxygen–such as sleep apnea–promotes IR and MetS 
factors31,125-130. Indeed, it has been reported that sleep apnea is linked to a higher prevalence of 
MetS than is obesity (without sleep apnea)128.  “Each additional apnea or hypopnea per sleep 
hour increased the fasting insulin level and HOMA-IR by about 0.5%”31, and experimental 
intermittent hypoxia in animals promotes IR and MetS-related factors131,132. In human studies, 
most relevant to human outcomes, sleep apnea–providing periods deficient in oxygen, the key 
energetic substrate–is linked to MetS, independent of obesity (though it may also contribute to 
obesity), and to each MetS factor31,125,133-139; while CPAP treatment for sleep apnea, in many 
studies, reduces IR and has been linked (in one or more studies) to benefit to each of the MetS 
elements133,135,140-146. The once-in-vogue construct, in describing lung disease, of “blue bloaters” 
vs. “pink puffers” is also germane–the former reflects the relative association of hypoxemia and 
attendant cyanosis to development of larger body habitus. (Tobacco smoke exposure can reduce 
oxygen delivery147–and reduce mitochondrial function148 and increase oxidative stress149–and is 
also linked to MetS150, despite an association to lower weight.) 
 
Ultra low calorie diets, fasting, and skipped or fewer meals should reduce MetS by the energy 
surfeit view. Rather, each promotes IR and MetS factors, relative to stable adequate calorie 
intake, consistent with the Starving Cell perspective151-154. Though weight loss occurs in the 
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short term, visceral fat deposition – and other features of MetS – are seen with longer term 
follow-up. Moreover, even intermittent calorie deprivation – even if overall calorie consumption 
is not low – appears to promote MetS, as evidenced by data on skipped meals and weight 
cycling. 
 
Simple-carbohydrate predominant macronutrient dietary profiles that may foster periods of 
relative hypoglycemia (and thus reduced cell energy) have on average promoted a MetS profile, 
at the same caloric intake, relative to diets higher in fat and protein118,155,156. (Diets relatively 
higher in simple carbohydrates, and lower in fat and protein, may cause an unopposed surge in 
insulin, leading to a drop in serum glucose.) Thus, the OmniHeart study showed that replacement 
of carbohydrates with fat or protein further improved metabolic parameters relative to a high 
fruit, vegetable, dairy diet alone156. (Genetics modulate the relationships157–as is likely the case 
for each risk factor and adaptation.) Fats and proteins relatively protect against hypoglycemia: 
dietary fat blunts the glucose rise from carbohydrates that fosters the insulin surge; and dietary 
protein promotes release of glucagon, which counteracts the glucose-lowering effect of insulin.  
 
MetS risk also rises in settings of increased energy demand.  
Energy demand considerations are not confined to exercise–which in fact supports energy, as 
well as expending it at the time of exercise, as reviewed below. Illness, trauma, inflammation, 
pregnancy, and cold temperatures (requiring energy diversion for heat generation), as well as 
increased hours awake, illustrate key settings in which energy demands are increased. Each of 
these sources of heightened energy demand has been linked to MetS158-163, directly contradictory 
to the energy surfeit model but in conformance with the Starving Cell perspective. Where tried, 
interventions that serve to protect cell energy in these settings have reduced MetS risk160. Cold 
weather requires energy expenditure for heat production. Seasonal related increases in each MetS 
factors–with MetS factors rising in winter–are widely described, and it is colder 
temperature164,165 (not, say, rainfall166,167) to which they are linked (Table 2 footnote e). 
Pregnancy involves diversion of energy resources to the fetus, and has long been recognized to 
lead, in a subset of gravid individuals who previously showed no evidence of these, to any 
combination of hyperglycemia and hypertension–termed in this setting “gestational diabetes” and 
“preeclampsia” (Table 1). These occur in presence or absence of excessive weight gain (beyond 
the amount “expected” to be needed to support the fetus), with excessive weight gain also arising 
in a subset who did not previously exhibit weight problems. Consistent with an association to 
energy adverse factors discussed here, a relationship of preeclampsia to oxidative stress has been 
reported168. Sepsis and other illnesses, as well as trauma, and surgery, boost energy demand and 
should, by the energy surfeit view, protect against MetS, but the opposite has been 
shown158,159,161-163,169. Sleep curtailment and reduced sleep hours (as well as poor sleep quality) – 
that is, greater time awake–increase energy demand, but are linked not to MetS protection, rather 
to occurrence of MetS and its elements170-176: Muscles are a major utilizer of energy, and muscle 
demand for energy is markedly reduced during sleep, while the major source of energy–oxygen 
through breathing–is sustained (unless sleep apnea is present). 
 
In each of these cases and in others, it is the factor linked to (episodes of) cell energy deficit that 
is linked to MetS risk; and the factor linked to protection against energy deficit that reduces risk. 
In each case, then, the findings are unexplained by the energy surfeit view, but concordant with 
the energy deficit one. Thus, the Starving Cell perspective is explanatory for a wide range of 
factors that drive, and protect against, MetS factors. The energy surfeit perspective repeatedly 
yields contradictions.  
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Consistently adequate access to energy is needed.  
Again, energy deprivation is problematic to cell viability even if temporary or episodic, even if 
to subsets of cells but not others, and even if “on average” (across time or cells) there is energy 
surfeit. Moreover caloric surfeit does not equate to cell energy surfeit. These points are essential 
in appraising the role of contributors to MetS. Thus, for example, skipped meals may promote 
energy deficit and MetS even if there is no dearth in overall calorie intake. 
 
Exercise both expends and supports energy – with potentially differing timecourses 
Although exercise expends energy at the time it is performed, regular moderate exercise has 
profound energetic benefits lasting long beyond the time of exercise, and extending to tissues 
beyond solely muscle  Exercise has been shown to increase mitochondrial number177, improve 
endothelial function178-180, venous return (increasing blood available to be oxygenated and 
redistributed to tissue), and cardiac as well as respiratory muscle function (benefiting oxygen 
intake and blood pumping capacity). Additionally, regular exercise enhances cellular antioxidant 
systems181 (oxidative preconditioning is germane). Exercise-associated conditioning of 
respiratory and cardiac musculature may further benefit oxygen intake and delivery of energy 
substrates and cofactors. 
 
Exercise thus has a mixed role in the Starving Cell perspective, because regular (moderate) prior 
exercise protects current cell energy through a spectrum of benefits. (Bloodflow benefits may 
improve oxygenation and energetics for some tissues even during exercise.) But current exercise 
expends current energy and may augment cell energy compromise when energy compromise is 
present or threatened. So moderate activity/exercise is generally favorable, when performed at 
intensities and in settings where exercise does not compromise cell energy. However, adaptive 
mechanisms may operate to limit exercise (by promoting fatigue or exercise intolerance), 
particularly in settings of current or threatened cell energy compromise.  
 
Explanatory Merits: 
The Starving Cell perspective is explanatory, accounting for which features comprise MetS.  
MetS as an entity has been deemed controversial by some182. There has been debate about 
whether MetS is “real” and whether features of MetS should be considered as a group27,182-184. 
The energy deficit perspective provides an understanding for why MetS factors statistically 
cohere, and it is reasonable to aggregate them. Thus, it supports MetS as an entity. 
 
It explains why a range of other energy supportive adaptations also commonly accompany them. 
Threatened cell energy drives features that support cell energy–by supporting supply and/or 
decreasing demand. These features include but are not limited to MetS factors. Effects include 
protection against low blood glucose–by promoting resistance to effects of insulin. They include 
increasing blood triglycerides–but also free fatty acids185-187 and fat deposition, particularly the 
metabolically active central fat188,189 as well as other ectopic fat. Ectopic fat is also metabolically 
active190,191 and also linked to energy deficit192 and to MetS. It has been shown in muscle191,192, 
heart190,192, pancreas193,194, liver192,195,196, kidney192, intestinal mucosa192 and perhaps brain197. 
Ectopic fat adaptations may be theorized to extend even to vascular fatty streaks and increased 
intima media thickness. (These cohere with Mets factors as early as childhood, and have 
precursors at that age including fetal energy deprivation32.) Thus, although free fatty acids and 
ectopic fat deposition are not a part of current MetS criteria, they serve as energy sources and are 
strongly related to MetS194. Adaptations include increasing BP: This helps to sustain adequate 
perfusion pressure particularly to relatively hypoperfused tissues–and thus delivery of oxygen, 
and other energy substrates and cofactors, boosting access to primary and supplemental sources 
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for energy in times of need. They extend further beyond MetS factorsa to include increased 
appetite and food foraging behavior to increase calorie intake35,172,175,199,200. Evidence even 
suggests mechanisms may include salt cravings, increasing (oxygen-delivering) blood volume. 
(In animals, stimulated increased venous return to the heart attenuated salt appetite201.)  
 
Mechanisms that, evidence suggests, adaptively lessen energy deficit by reducing energy 
demand include increased sleep duration128,170,202, reduced resting metabolic rate35, increased 
fatigue203 and reduced physical activity energy expenditure204.  
 
Thus MetS factors are those among the adaptive factors that are frequently measured in the 
clinical setting (or for waist circumference, evident from casual inspection), accounting for the 
recognition that these aggregate–and for the fact that it is these that are defined to comprise 
MetS. Yet adaptive factors beyond MetS range from increased appetite/food seeking behaviors 
to increased sleep duration to increased free fatty acids to increased ectopic fat deposition–
factors disparate in character but homogeneous in conferring energetic protection. And 
importantly, adaptive features include increased calorie intake and reduced exercise expenditure, 
leading the features of the energy surfeit hypothesis to be among the mediators of the energy 
deficit (or Starving Cell) one.  
 
Thus, while the perspective supports the aggregation of MetS factors based on many common 
antecedents, common functions, and common correlates, it challenges whether the factors 
viewed as comprising MetS are in fact all those which bear inclusion. These might be argued to 
be merely the most clinically available of a set of adaptive factors that share common 
antecedents and accompaniments, but free fatty acids, ectopic and visceral fat and other 
adaptations cohere with them.  
 
It explains the relevance and direction of effect of many risk factors and protective factors–
providing a unifying perspective for what have been viewed, by some, as a haphazard 
aggregation of factors. 
As Table 1 reviews, it accounts for the spectrum of factors that promote and defend against 
MetS; and for the direction of impact of MetS risk factors and protective factors.  
 
It explains other MetS correlates–including markers that are also energy related, but also markers 
that are not directly energy related.  
The perspective explains why numerous other measurable markers are linked to MetS (Table 2 
and footnotes). For instance, other consequences of MetS-causes–like oxidative stress–are linked 
to MetS. Thus, oxidative stress triggers cell apoptosis205-207 which activates coagulation and 
inflammation pathways208. This predicts the widely observed findings that MetS, also promoted 
by oxidative stress, is linked to elevated fibrinogen209,210 and to inflammatory markers like 
hsCRP210-220. Uric acid, which has been referred to as an “independent component of metabolic 
syndrome”221, rises in response to oxidative stressors, serving vital antioxidant functions222,223. 
                                                 
a
 The fact that MetS factors sometimes present in isolation is not unexpected. Genetic and other factors modulate the 
balance of adaptations, and which arise preferentially. Only one adaptation may, at a given point in time, arise – and 
may perhaps suffice. However, processes driving the first adaptation may persist. Thus persons with one adaptation 
are at heightened likelihood of developing others over time. Additionally, some adaptations can themselves drive 
energy deficit when in excess. Thus elevated glucose can promote oxidative stress198. Tsuneki H, Sekizaki N, 
Suzuki T, et al. Coenzyme Q10 prevents high glucose-induced oxidative stress in human umbilical vein endothelial 
cells. Eur J Pharmacol. Jul 2 2007;566(1-3):1-10.; and obesity may, for instance, promote reduced exercise which 
may reduce mitochondrial number, endothelial function, and antioxidant production.  
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Similarly, gamma glutamyl transferase (GGT), which has been found to be elevated in 
MetS70,221,224 and is also considered to be a “marker” of MetS221, provides antioxidant 
adaptations to oxidative stress, by “breaking down extracellular glutathione and making its 
component amino acids available to the cells”213,225. 
 
It explains other MetS correlates–including markers and outcomes that are not directly energy 
related.  
Just as these explain a number of markers linked to MetS, they also explain a number of health 
correlates. Oxidative stress, inflammation, mitochondrial dysfunction (and the factors that cause 
them), or energy deficit generally, are linked both to MetS, and to a range of outcomes extending 
to cancer226 and depression227, thus promoting the epidemiological association of MetS to such 
outcomes. 
 
It explains bidirectional associations of some factors to MetS 
It accounts for bidirectional cross-sectional associations of a number of factors to MetS that are 
generally considered enigmatic. For instance, short and long sleep duration are both linked to 
MetS176,228. The present perspective explains this bidirectional association, as cause and 
consequence. Thus, factors linked to energy deficit (such as short sleep duration) are linked to 
MetS as causes. Factors linked to energy support (prolonged sleep duration) are linked to MetS, 
because, like MetS factors, they reflect fellow adaptive consequences of energy deficit. This 
generates testable predictions: prospective experimental study can evaluate whether, as 
proposed, the one serves as a contributor, the other as fellow consequence. It provides an 
alternative account for why a range of health outcomes–from depression to cancer to cognitive 
and functional loss to leg cramps and chronic pain–are linked to MetS–via common cause18,21,229-
232
. Cell energy deprivation and its causes–like oxidative stress or mitochondrial dysfunction–
may concurrently foster MetS and such conditions227, promoting an epidemiological association.  
 
The Starving Cell (or energy deficit) vantage reconciles previously conflicting perspectives of 
MetS. For instance, it adjudicates between glucocentric vs. lipocentric194 perspectives, by 
subsuming both under an energy-centric view.  
 
It accounts for why aggressive measures to reduce one MetS factor seem commonly to lead to 
promotion of others–a sort of “push me, pull you” or “whack-a-mole” phenomenon. 
Niacin233 and statins (especially high dose) improve lipids but may raise glucose and risk of 
diabetes234-237; and high doses are linked to reports of weight gain238. Aggressive calorie 
restriction reduces weight (in the short term) but promotes insulin resistance and diabetes151. 
Beta blockers, thiazides and even salt restriction lower blood pressure but adversely affect serum 
lipids (unless attended by concurrent energy-supporting interventions)239-241. Thiazides reduce 
blood pressure but promote glucose elevations242. Insulin and sulfonylureas lower glucose but 
promote weight gain243-245. Thus, in numerous instances, improvement of one MetS factor, unless 
attended by energy support, has led to increased risk of other MetS factors arising. In contrast, 
interventions that improve MetS factors “by” supporting energetics and/or antioxidation, such as 
cinnamon246-248, fruits and vegetables, and coenzyme Q1060,64,249-252, benefit many MetS factors 
concurrently. 
 
It explains MetS predictive “paradoxes”–why MetS does not portend adverse outcomes, or 
indeed portends favorable outcomes, in some groups. And it unifies these groups as those 
bearing energetic challenges. 
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It accounts first for why lesser control of MetS factors may arise in settings of energetic 
challenge, produced by increased energy demand and/or reduced supply (e.g. illness, injury, 
surgery and in older elderly253). And it accounts for why MetS itself254, and individual MetS 
factors, lose their adverse prognostic portent, or are even linked to more favorable mortality 
outcomes (and sometimes even fewer cardiovascular events), in such groups254,255. Subjects who 
are overweight or even obese have shown “paradoxically” lower complication rates and 
mortality than those who are underweight or normal weight in a range of settings of impaired 
energy supply or increased demand, termed an “obesity paradox” or “reverse epidemiology”255. 
This has been reported for older elderly255 256,257, persons with heart failure258-261, wasting 
disease262, cardiovascular disease260,263,264, chronic kidney disease265 (recall the kidney 
manufactures erythropoietin), undergoing dialysis260,266, percutaneous coronary 
interventions267,268 and nonbariatric surgery269 and for persons with cancer or AIDS266. Similar 
“paradoxes” are observed in such settings for lipids257,266,270 and blood pressure266. These settings 
appear different – but share in common adverse energy supply:demand balance. 
 
It explains why even in studies of broader samples, use of higher dose treatment to attain full 
“control” of MetS factors (producing normal values) relative to “suboptimal” control, has often 
been neutrally or even unfavorably linked to mortality. 
This is consistent with adaptive function of MetS factors. This has been observed for blood 
glucose271, lipids272, blood pressure273, and weight257,274. It is a prediction of the Starving Cell 
perspective that the energetic vulnerability of the population will modulate the degree to which 
full control will be disadvantageous. 
 
Predictive Merits 
The Starving Cell perspective is not merely explanatory: It is predictive.  
Table 3 shows additional predictions and implications afforded by this hypothesis. Some 
predictions draw from the above – e.g. that shorter sleep duration may cause MetS, while longer 
sleep duration may follow from other energetic challenges that concurrently drive MetS; or that 
other conditions with highly adverse energetic balance will drive – and benefit from – metS 
features. Some predictions are contrary to current thinking. For instance, stringent salt restriction 
may have adverse rather than favorable long-term consequences to MetS factors, particularly in 
perfusion-pressure dependent individuals. (This excludes settings like congestive heart failure, in 
which salt restriction increases effectiveness of circulation and thereby improves cells’ access to 
energy.) Salt restriction may even promote development of hypertension itself in some–as some 
evidence already suggests275. Indeed, other antihypertensive approaches including propranolol 
and clonidine have been linked to instances of paradoxical worsening of blood pressure276,277. 
(This could be viewed as a “push me, pull me” phenomenon, contrasted with the “push me, pull 
you” one described above.)  
 
It predicts that adding nutrient dense, antioxidant promoting foods, such as adding a fruit each 
day (possibly even a piece of dark chocolate) or supporting vitamin D adequacy, may reduce 
MetS/obesity risk in many even if no other calories are removed; and that the benefit of 
antioxidant supportive interventions may be influenced by the existing oxidant/antioxidant 
balance. Along similar lines, it predicts that adding nutrient dense elements to a food (for 
instance, adding caraway, sesame and poppy seeds to a plain cracker) will favorably rather than 
adversely alter that food’s impact on MetS, despite increasing calories and fat. It predicts that 
“low calorie” and even “no calorie” foods (or beverages, or even water) with prooxidant 
additives, contaminants or chemically modified ingredients (such as trans fats, mercury as a 
contaminant of high fructose corn syrup, arsenic in poultry feed or as a contaminant of drinking 
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water) will foster MetS disproportionate to the calorie count – or in the absence of any. It 
predicts that cell energy support, more than calorie restriction and often even in its absence, will 
produce sustained benefits to MetS; and that indeed calorie restriction will not produce sustained 
benefits to MetS unless cell energy is fully supported.  
 
Adaptive mechanisms are implemented across time and spanning a range of adaptations. It is 
predicted that interventions that reduces one MetS factor in the short term (and do so without 
supporting cell energy), will confer less favorable effects with longer term follow-up, when other 
MetS elements (or adaptations) are examined, or when imposed in individuals with impaired 
energy supply (e.g. older elderly) or high demand–that is, it predicts a generalization of the push-
me pull-you thesis.  
 
Discussion 
Recap 
The Starving Cell perspective proposes a fundamental rethinking of MetS as an adaptive process 
for cell energy protection. It is new, but has been prefigured by the Thrifty Gene hypothesis, 
whereby energy deprivation in prior generations increases risk of obesity and MetS when access 
to calories is restored; and by evidence that fetal calorie deprivation promotes obesity and MetS 
in later life. It is shown that resulting accessory sources of cell energy include MetS factors, but 
extend beyond them, to increased free fatty acids, ectopic fat, and appetite35,172,175,199,200; and 
reduced energy demand via increased sleep duration and fatigue203,278-285, and reduced activity204. 
It is suggested that these adaptations derive from the central role of cell energy in cell and 
organism survival, providing strong impetus for evolutionary development of a panoply of 
adaptive mechanisms to preserve cell energy following settings of shortage – with details of 
implementation influenced by genetic and other determinants. 
 
Many factors contribute to MetS beyond calories consumed and exercise engaged in. Adverse 
effects on cell energy supply-demand balance represent a unifying thread. A range of forms of 
impaired energy supply, including (periods of) inadequate calorie intake, hypoxemia, impaired 
access to energy from fat cells, or mitochondrial dysfunction; or elevated energy demand, from 
illness and injury158,159,161-163, pregnancy, cold, or sleep deprivation, are linked to risk of MetS. 
Conversely, factors that defend against impaired cell energy defend against MetS elements, and 
help to reverse them. 
 
Context: Reconciling this with the Energy Surfeit view; Building on Prior Findings 
The energy surfeit and energy deficit views should not be viewed as fundamentally in 
opposition. Cell energy deficit adaptations include increased appetite/calorie intake35,172,175,199,200; 
and reduced exercise204. These are adaptations to energy need precisely because these can 
contribute to cell energy reserves, via increased fat. Similar in relation to exercise, fatigue, 
exercise intolerance and reduced activity are seen in settings of energy impairment278-280,282-285–
and are reportedly common in MetS203; and treatments to improve cell energy have reduced 
fatigue281. Thus, features of the energy surfeit perspective–increased calorie consumption and 
reduced energy expenditure through activity–are among adaptive mediators of the Starving Cell 
view. The claim is thus not that the magnitude of the food calorie balance, when it is positive, 
has no role in fat deposition. Rather, the claim is that prior and intercurrent episodes of cell 
energy deficit may increase the drive for calorie surfeit; may increase the avidity of fat 
deposition at a given level of calorie surfeit; and may also increase the likelihood of other 
elements of MetS with or without the presence of such fat deposition. (Indeed, more successful 
deposition of subcutaneous fat, and access to energy from it by better vascularization, may 
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reduce risk of MetS per se.) Moreover, it is recognized that MetS factors, in their extreme forms, 
may themselves conduce to energy impairments: marked obesity may restrict exercise-related 
energy supports, high glucose may promote oxidative stress198, hypertension may promote 
ischemic events restricting energy substrate and cofactor delivery. While increased calorie intake 
and reduced activity can occur without antecedent or intercurrent cell energy deficit–and may 
perhaps nonetheless promote weight gain  –among those who do gain weight or are obese, 
evidence is consistent with the proposition that development of MetS remains conditioned by 
cell energetic impairment, and factors that dispose to it109,117,120,128,286. 
 
The connection to MetS elements of the risk factors cited–such as oxidative stress and 
mitochondrial dysfunction–have individually been previously noted (at least for most MetS 
features). However, the consolidation of multiple findings across many domains into a central 
theoretical framework represents an innovation with significant predictive ramifications. A 
strength is the focus on human data (see Tables), with clear relevance to human application.  
 
Limitations 
This assessment is by no means comprehensive. Numerous other examples could be adduced to 
support the Starving Cell thesis. The mechanisms by which the varying forms of energy 
compromise are translated to promotion of MetS and other adaptive elements are extremely 
important, but must be a subject for a different venue. These include mediation by effects on 
leptin or ghrelin, steroid hormones and nuclear receptors and catecholamines–and of course 
insulin resistance, among other mechanisms175,287-291. Nor does this paper focus strongly on 
mechanisms by which MetS factors and adaptations may themselves potentiate the MetS 
process–e.g. via glycation endproducts292,293 . These latter mechanisms provide possible 
prospects for benefit when MetS elements are partially corrected, particularly in individuals who 
don’t demand the energy support just now294-296. 
 
Implications 
We live in a time and place of ample access to calories for most; and reduced activity in daily 
life. These may render counterintuitive the concept of cell energy deficit as a contributor to the 
rise in obesity and MetS. However, as emphasized here, sufficient cell energy does not equate to 
a time-averaged tally of calories consumed in food, and expended in exercise. It depends on 
energy adequacy at all times, and on adequacy of the range of factors required for energy 
generation. Secular shifts have adversely affected numerous cell energy determinants. The 
approach to regular meals is often less formal–including skipped meals153; as is the approach to 
balancing meal composition (including fruits/vegetables83, fat and protein155). Attempts at weight 
loss via calorie-restricted diets151,152 are common. So too are meals and snacks that are low in 
fat–and often nutrient poor and high in simple carbohydrates, fostering insulin release and 
potential for hypoglycemia. Modern crop production processes (for fruits, vegetables, grains) 
may lead soil micronutrients to be depleted by each growth cycle without being replenished. This 
may cause some foods to be impoverished in micronutrients and antioxidants.  
 
Factors that promote oxidative stress and mitochondrial dysfunction are becoming omnipresent. 
Examples include rising exposure to pesticides and herbicides in landscaping and foods297-302, 
many nonprescription and prescription medications95,303-305, chemically modified food 
                                                 

 The concept of weight set points, if attended by any validity, suggest this need not necessarily be the case81.
 Foss YJ. Vitamin D deficiency is the cause of common obesity. Med Hypotheses. Mar 2009;72(3):314-
321.. 
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ingredients306,307, personal care products, air fresheners, fabric softeners, clothes and furnishings 
with formaldehyde, stain retardants and fire retardants, electromagnetic fields and microwave 
radiation from appliances and cell phones308,309, petroleum and combustion products310-314, and 
contaminants in air, food, and water315,316–among numerous other sources. Sleep hour restriction 
is common–and sleep apnea is prevalent (I suggest in consequence of the similar energetic 
deficits to those that promote MetS–impaired cell energy to muscles that hold open the airway in 
sleep– e.g. arising from oxidative stress, vitamin D deficiency, etc–may promote sleep apnea 
which in turn aggravates the energy deficit. Conditioning airway muscles through exercise in the 
form of singing has been linked to reduced snoring317,318; and treatment of sleep apnea with 
CPAP–restoring oxygen adequacy to the airway muscles–increases airway caliber and reduces 
airway collapsibility319). Each of these factors adversely influences cell energy, and by 
hypothesis relatively conduces to MetS–potentially contributing to the MetS epidemic. For 
pregnant women, many of these factors, as well as older maternal age, may adversely affect 
energy to the mother, contributing to risk of preeclampsia and gestational diabetes (and later risk 
of MetS); and to the fetus, disposing to MetS factors in childhood and later life. It is proposed 
that these provide targets for intervention, in addressing the epidemic of MetS, that may both 
complement–and also pointedly depart from–those commonly considered.  
 
If the chief underlying fundamental change driving the epidemic were solely the number of 
calories taken in vs. expended, approaches that instruct people on the number of calories to aim 
for, and which foods have how many calories, should have had success–if not universal, then 
widespread–in producing sustained weight loss. But even well-educated people with good 
understanding of calorie number, in whom willpower and self-discipline are strong as evidenced 
in other realms of their life, are seldom able to sustain weight loss long-term by means focused 
on calorie restriction alone (despite ability to initially lose some weight–indeed perhaps, in a 
sense, because of it). Moreover, evidence suggests that mortality may be increased, rather than 
reduced, in those who are successful in thus achieving sustained weight loss274. This suggests 
other factors are operating. 
 
Conclusion 
A thesis is reviewed, termed for simplicity the Starving Cell thesis, by which MetS factors arise 
as an adaptation for cell energy protection. This perspective provides a unifying framework for 
why MetS factors statistically cohere; for why other energy adaptations cohere with them; and 
for which factors promote and protect against MetS factors. It explains a suite of findings that 
appear paradoxical under the lens of the energy surfeit view. It accounts for numerous other 
findings: for which markers and conditions correlate with MetS; for why some factors show 
bidirectional associations with MetS; for why “paradoxical” relations of MetS factors to 
mortality occur in populations with impaired energy supply or increased demand, for why 
correction of one MetS factor–except by energy supportive interventions–commonly worsens 
another; for why tight control of MetS factors often has neutral or adverse clinical impact (unless 
by means that control MetS factors by supporting cell energy); for why there is greater 
vulnerability to tight control in certain settings (older age; impaired energy supply, higher energy 
demand). Roles for energy deficit and energy surfeit are reconciled. 
 
This thesis generates a range of testable predictions, some contrary to current thinking. It has far-
reaching implications. It suggests fundamental changes–complementary and sometimes contrary 
to current approaches–to strategies to defend against development of MetS, to efforts to reverse 
it when it arises, to approaches to mitigate the impact of MetS–and to societal corrections aimed 
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at arresting the worldwide epidemic of MetS and DM that increasingly afflicts individuals of all 
ages, ethnicities and walks of life1-4,320.  
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 Table 1.  Risk Factors and Protective Factors for MetS Cohere with the “Starving Cell”  
(Energy Deficit) Perspective 
 (see Table Footnotes) 
 
 Expected Direction of Effect  
on MetS 
Actual Effect  
on MetS 
 Predicted by 
Energy Surfeit 
Hypothesis 
Predicted by  
Starving Cell 
Hypothesis 
 
The Evidence 
Reduce cell energy supply    
Sleep apnea a Decrease ▬ Increase  Increase  
Skipped meals, fewer meals b Decrease ▬ Increase  Increase  
Ultra low calorie diets b Decrease ▬ Increase  Increase  
Hypoglycemia promoting vs. 
protective macronutrient 
composition c 
Decrease ▬ Increase  Increase  
Mitochondrial dysfunction d Decrease ▬ Increase  Increase  
Oxidative stress e Decrease ▬ Increase  Increase  
Older age f Decrease ▬ Increase  Increase  
Micronutrient deficiencies g Decrease ▬ Increase  Increase  
Mixed increased demand and 
increased cell energy supply 
   
Exercise h Increase/Decrease Increase/Decrease Decrease  ▬ 
Increased demand    
Sepsis, Illness i Decrease ▬ Increase  Increase  
Trauma i Decrease ▬ Increase  Increase  
Pregnancy j, k Decrease ▬ Increase  Increase  
Sleep restriction a Decrease ▬ Increase  Increase  
Protection against reduced 
energy supply 
   
CPAP Treatment for sleep 
apnea a 
Increase  Decrease  ▬ Decrease ▬ 
Coenzyme Q10 
supplementation d, e, g 
Increase  Decrease ▬ Decrease ▬ 
Antioxidant rich dietary 
patterns e 
Increase  Decrease ▬ Decrease ▬ 
Appetite increases represents one among a set of adaptive mechanisms which contribute to 
fat increase in this and other settings35,172,175,199,200. 
 
Table Footnotes Contain Key Evidence: 
a. Sleep apnea and CPAP treatment: The energy surfeit model would predict that obstructive sleep apnea (OSA), 
by reducing inspired oxygen and consequently energy production during sleep, would foster negative energy 
balance, and promote weight loss and reduce MetS. Instead, OSA is powerfully linked to increased risk of IR, MetS, 
and each MetS element–including elevated glucose, blood pressure, dyslipidemia, weight and abdominal fat31,125,133-
139
. While it is often though of as a consequence of obesity, in fact OSA (also) contributes to central obesity290. 
Moreover, in many studies treatment (with continuous positive airway pressure or CPAP) has benefited IR140,143,321 
and each element of MetS -- including visceral fat125,133,135,141,142,144-146,322,323. OSA is linked to a higher prevalence of 
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MetS than obesity (without OSA)128. Consistent with a causal role for hypoxia, experimental intermittent hypoxia in 
animals is linked to IR and to MetS-related factors131,132. 
 
b. Skipped meals; fasting; ultra-low calorie diets: Each of these entail prospects for energy insufficiency. The 
energy surfeit hypothesis would suggest reduced MetS and also weight loss should ensue from each. Instead, these 
are linked to increased risk of insulin resistance, long-term weight gain, dyslipidemia and MetS151-153. More vs. 
fewer meals/day–conferring protection against periods of cell energy depletion— is linked to lower BMI and a more 
favorable lipid ratio153. Adaptive mechanisms (following on these and other reasons for energy deficit), along with 
MetS factors per se, may include (subsequent) increased hunger/ calorie consumption to benefit energy supply35; 
and from the demand side, reduced resting metabolic rate35,204, and reduced physical activity energy expenditure204. 
Thus, though calorie deficit may serve as the instigating factor for MetS, it may operate through the appearance, and 
indeed the reality, of relative calorie surfeit–more calories in, less energy expended. Settings engendering a larger 
adaptation during dieting (greater reduction in physical activity energy expenditure) may on average reflect a larger 
energetic challenge to cells. This may contribute to the observed larger adaptation later–contributing to an 
association between magnitude of the adaptation during the diet; and the subsequent weight regain204.  
 
c. Macronutrient Composition in Relation to Energetics: A high protein high fat low carbohydrate (Atkins-style) 
diet improved multiple MetS factors relative to a low fat high carbohydrate (Ornish-style) diet, in the randomized A 
TO Z diet trial - a trial that, unlike some, succeeded in producing markedly different macronutrient diet 
compositions in the randomization groups, in the intended direction155. This occurred despite no difference in 
calories consumed or exercise expended155, inconsistent with predictions from the simple food/exercise calorie 
tradeoff view. However, it is compatible with the Starving Cell view: simple carbohydrates lead to a rise in glucose, 
which leads to a surge of insulin causing glucose to fall and producing relative hypoglycemia. It is this 
hypoglycemia, and the resulting relative energy deficit, that fosters development of insulin resistance (to protect cell 
energy in the future). Fat consumed with the carbohydrates blunts the rise in glucose (which leads to the insulin 
surge, and resulting drop in glucose) while protein consumption leads to release of glucagon, counteracting the 
glucose-lowering effects of insulin. Similarly, the OmniHeart study showed that substitution with fat or protein for 
some of the carbohydrates led to additional benefit to MetS elements over a high micronutrient (fruit, vegetable, 
dairy rich) diet156. Of note, observational studies have also reported an inverse relation of protein and fat 
consumption to MetS118. (A subsequent analysis showed that likelihood of success in weight loss in the low fat vs. 
low carbohydrate diet was strongly influenced by several genes157) High fat consumption is also linked to lower risk 
of stroke324, and outcome strongly linked to MetS16. 
 
d. Mitochondrial dysfunction: Mitochondrial function is central to cell energy generation. By the energy surfeit 
view, impaired mitochondrial function and consequent impaired energy production efficiency should reduce energy 
and protect against MetS. Yet in animal studies, mutations “that phenotype as decreased OXPHOS efficiency” show 
“subsequent development of impaired glucose tolerance”108. The same is true in humans48, in whom mitochondrial 
dysfunction has been linked extensively to diabetes45,48,325-336, to IR and MetS43,44 to obesity and each MetS 
element44-47,49-52, as well as ectopic fat deposition52,192,337, a strong MetS correlate338,339. Since mitochondrial DNA 
mutate at a rate 10-1000 times that of nuclear DNA, in part due to their proximity to reactive oxygen species69, 
mutations accrue with age and may propel age-related increases in MetS and diabetes42,48.   
 Additionally, drugs with mitochondrial toxicity are associated with increased risk of MetS. This is true for HIV 
medications76,77 and the post-transplant setting340-344. Additionally, antipsychotic agents, which are now recognized 
to be powerfully linked to MetS factor elevations78,80, also cause oxidative stress and mitochondrial 
derangements78,79. 
 Dietary supplements with coenzyme Q10 (involved in mitochondrial electron transport and as an endogenous 
lipophilic antioxidant57) improves cell energy, bypassing a range of respiratory chain defects53-55. Rather than 
promoting MetS (as the energy surfeit hypothesis would predict), coenzyme Q10 (and other mitochondrial 
supportive nutrients) has improved blood pressure249,250, triglycerides and HDL60,251 and glycemia252. In Praeder 
Willi syndrome, a condition involving starvation feeding behaviors and obesity, as well as hypersomnolence, 
coenzyme Q10 supplementation reduced feeding behaviors–and also excessive sleep hours64.          
 
e. Oxidative stress (OS): OS is powerfully linked to MetS and to each of the MetS subcomponents, and higher OS 
relates to greater number of MetS components93,94,106. OS is both a consequence of mitochondrial dysfunction101,102; 
and a cause (mitochondria are a primary target as well as source of reactive oxygen species99,102,345, and numerous 
exogenous oxidative stressors induce mitochondrial impairment–see Mitochondrial Dysfunction, above.  
 Fruits, vegetables, nuts, legumes, chocolate and coffee are each rich in antioxidants107,346 and each is linked to 
reduced risk of IR/MetS and diabetes111-114,347. (Coffee also has diuretic and other effects that may be energy 
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adverse, and effects on the heart are favorable or adverse depending on genetic factors348.) In a human study, the 
combination of alpha lipoic acid and acetyl L-carnitine, benefiting OS and mitochondrial function, significantly 
reduced blood pressure in the subgroups with hypertension and with MetS250 (L-carnitine has also been shown to 
reduce triglycerides in animal studies349). Similarly, coenzyme Q10 supplementation–see Mitochondrial 
Dysfunction– benefits oxidative stress and also mitochondrial function, and benefits multiple elements of MetS.    
 Mounting evidence links a range of environmental oxidative stressors to MetS and its elements. For instance, 
arsenic mediates its toxicity through OS350; arsenic exposure (e.g. arsenic contaminated water) is linked to 
hypertension351,352, diabetes352,353, adverse lipid effects352,354, and MetS352  Arsenic causes weight gain in animals 
(reflected in its use in animal feed–including food animals - to foster growth355).  Acetylcholinesterase inhibitors 
(AChEi), such as organophosphate and carbamate pesticides also exert their toxicity through oxidative stress356-358. 
In animal studies, exposure is linked to hyperinsulinemia and hyperlipidemia359. Moreover human groups with high 
rates of AChEi exposure360 have shown elevated rates of weight gain361-363 and hypertension362,364,365; follow-up for 
diabetes and other MetS factors is warranted.       
 Some oxidative stressors may promote MetS through mixed means. Trans fats, common in fast foods and 
purchased baked goods366,367, are oxidative stressors306,307 and block glucose uptake into muscle. They promote IR368-
370
, raise TG and lower HDL307,369,371, increase fatty acid synthesis307, promote ectopic fat deposition370, and are 
obesogens, promoting visceral fat deposition even in absence of caloric excess368. Bisphenol A, which leaches from 
plastic food containers and is detected at high rates in sampled humans372, is an oxidative stressor373-377 (as well, 
however, as endocrine disruptor378,379) with OS playing a major role in its cytotoxicity377. It disrupts mitochondrial 
function (in cell culture studies)376. Bisphenol A is a recognized obesogen378-380, induces insulin resistance378 and 
adversely affects lipids in animal studies380. However, these consequences have been primarily ascribed to steroid 
hormone effects372,378,379 (which in turn can affect oxidative stress as well as mitochondrial function, among 
numerous other factors).♠    
 Of relevance, however, is the phenomenon of oxidative preconditioning, by which time-limited exposures to 
certain oxidative stressors may lead to sustained adaptive increases in endogenous antioxidant mechanisms that may 
provide cross-protection against other oxidative stressors123,124; benefits of exercise may include such oxidative 
preconditioning. 
 
f. Age and Older Elderly: Increasing age is linked to IR44 and MetS382, “despite” (by the energy surfeit view), or in 
association with, age-related cell energetic declines (arising from accrued mitochondrial dysfunction383, endothelial 
dysfunction, cardiopulmonary function decline, atherosclerotic restriction of flow, etc). In younger individuals 
where bioenergetic defects are not typical, presence of MetS factor elevations (statistically) signal greater presence 
of energetic deficits–and thus portend worse outcomes. (In addition, marked elevations, at least, in MetS factors may 
themselves contribute to worse outcomes.) In elderly, MetS loses adverse mortality portent254. In older elderly, 
energetic impairments are the norm, via age-related mitochondrial dysfunction (among other factors)383,384. In this 
setting, absence of MetS factor elevation may signal failure of successful adaptation. Studies have linked at least 
moderate elevations in blood pressure385-387, total or nonHDL cholesterol257,388-390, weight/BMI257,391,392, fat including 
visceral fat or waist circumference391, and possibly glucose393 to lower mortality relative to “normal” values in older 
elderly. This is compatible with the finding that healthy centenarians, with no history of coronary disease, 
commonly show MetS style dyslipidemia–a finding that may be expected in the energy deficit view, though 
portrayed as “paradoxical”253. 
 
g. Micronutrient deficiencies commonly attend obesity (and MetS) (epidemiologically)64,394. If obesity and MetS 
were explicable simply as more food taken in, higher levels of nutrients would be expected to accompany obesity 
and MetS. Instead, measured nutrient deficiencies are commonly seen, and lower micronutrient intake has been 
linked in humans to higher rates of MetS118. Since nutrient deficiencies impair cell function–and many micronutrient 
                                                 
♠
 C-reactive protein, a marker of inflammation, is also strongly linked to MetS and its elements. Oxidative stress and 
inflammation are strongly related, with the former contributing to the latter (e.g. via triggering of inflammatory 
processes when OS induced apoptosis occurs)208. Reutelingsperger CP, van Heerde WL. Annexin V, the 
regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. Jun 
1997;53(6):527-532.  In one study, CRP related strongly to a marker of oxidative stress 8-iso-PGF(2alpha), r =0.73 
unadjusted (p < 0.001), 0.60 adjusted (p=0.0001); but OS showed the more strongly significant connection to 
essential hypertension (p < 0.0001 vs p < 0.001)381. Cottone S, Mule G, Nardi E, et al. Relation of C-reactive 
protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens. Mar 
2006;19(3):313-318. offering the possibility that the effect of inflammation may be substantially through its relation 
to OS. 
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deficiencies adversely affect oxidative stress and/or mitochondrial function109–this is compatible with the Starving 
Cell hypothesis–and inconsistent with the calorie surfeit view. 
 Vitamin D deficiency has been linked to MetS and specific MetS elements–including waist circumference, 
HbA1C, BMI, blood pressure triglycerides and HDL115,116,120,395. Within severely obese subjects, high vitamin D was 
protective vs. MetS–high blood pressure, high triglycerides, low HDL, and high blood glucose396.• 
 Coenzyme Q10 is a vitamin-like substance that, like vitamin D, is endogenously produced but not necessarily 
sufficiently to supply needs. Supplementation has been linked to improvement in systolic and diastolic blood 
pressure59,252,397, triglycerides59, HDL59,60,398, glucose59 and HbA1C252, insulin59, and hunger64 (also LDL60). 
 Both vitamin D110 and coenzyme Q10399 have roles in mitochondrial function; additionally, Q10 is an important 
(according to some,  the important) endogenous lipophilic antioxidant400,401 while vitamin D protects against a major 
consequence of oxidative stress, i.e. mitochondrial-related apoptosis (vitamin D)402-404 
 In animal studies, a vitamin A deficient diet lead to marked increased adiposity and increased weight gain405. In 
human observational data, vitamin A and E consumption are inversely related to MetS118. Vitamin A and vitamin E 
deficiency promote oxidative stress, mitochondrial dysfunction, and impaired energetics108,406,407.  
 
h. Exercise: Exercise has bidirectional effects on cell energy. At the time exercise is undertaken, it expends energy, 
with longer exercise expending more energy, and hard exercise more likely to lead to cell energy deficit particularly 
at the time of exercise (and potentially for a time after, e.g. via induction of oxidative stress). However, regular mild 
to moderate aerobic exercise benefits multiple processes (above) that protect against cell energy deficits, with 
protections extending far beyond the time of exercise. (See above, oxidative stress, for brief discussion of oxidative 
preconditioning.) Mild to moderate intensity aerobic exercise benefits MetS elements including blood pressure408-410, 
lipids (particularly HDL and triglycerides)409,411, and glucose412,413. The energy surfeit hypothesis would predict 
greater benefit with higher intensity exercise. The energy deficit hypothesis would predict greater likelihood of cell 
energy compromise with high intensity exercise, and less benefit to MetS factors relative to mild-moderate exercise. 
Randomized trial data on hypertension support the latter410. It is predicted here that the level of exercise that will be 
energetically “intensive” will depend on individual energetic factors (including mitochondrial and oxidative status). 
 
i. Illness, injury, surgery: Illness (including sepsis) and trauma pose energy demands and lead to hypermetabolic 
states. By the energy surfeit hypothesis this should retard development of MetS elements. Yet these conditions 
strongly promote MetS elements, driving increases in IR158, hyperglycemia158, and MetS dyslipidemia 
(hypertriglyceridemia and drops in HDL)159,161-163. Surgery increases energy demands, and preoperative fasting may 
reduce energy supply. Postoperative insulin resistance has been reported, including for elective surgery, and 
preoperative carbohydrate loading has been reported to lead to clinical benefits169. Moreover, “paradoxes” (e.g. 
obesity paradox) such as those observed in elderly are also observed in these settings of elevated energy 
demand255,256,258,259,266-269. 
 
j. Pregnancy Effects on the Offspring: Low maternal calorie intake during pregnancy, by the energy surfeit 
hypothesis, should be linked to lower risk of MetS in the offspring. Rather it is associated with risk of MetS and its 
sequelae (such as increased aortic intimal medial thickness32) in the offspring414. (Low birthweight/ intrauterine 
growth retardation415, which suggest poor access to energy substrates for any of a range of reasons, is also linked to 
development of MetS, and sequelae415, in the offspring.) Indeed, in utero effects represent a domain in which 
adaptive effects are well recognized. This represents a special case of the larger principle espoused.    
 
k. Pregnancy Effects on the Mother: Though pregnancy is a condition of increased energy demand, it is associated 
with increased risk of elevated blood pressure (preeclampsia) and diabetes (gestational diabetes) -- as well as 
excessive weight gain. It is predicted that these conditions will be found to be more common in women with 
oxidative stress, mitochondrial dysfunction and other correlates of low energy (Preeclampsia has already been linked 
to oxidative stress168.)  It is widely recognized that adaptive increases in hunger and calorie intake occur in 
pregnancy. It is predicted, however, that cell energy deficits rather than surfeits will drive preeclampsia and 
gestational diabetes–as supported by the relation of preeclampsia to oxidative stress168.   
 
l. Sleep restriction/sleep deprivation: Since more calories are expended during activity than rest, by the energy 
surfeit view, sleep restriction would be expected to drive weight loss. Instead sleep restriction is linked to greater IR, 
appetite dysregulation, weight gain, blood pressure, glucose intolerance and MetS170-175. While “the” function of 
                                                 
•
 The relation lost significance with a set of adjustments that included BMI, fat mass, and season. However, this 
represents overadjustment because several of these factors are or may be in the vit D/ MetS causal pathway, 
contributory to vitD deficiency (season) or helping mediate the association (fat mass). 
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sleep is often stated to be unknown, the heretical suggestion is proffered that one function of sleep is: rest. Sleep 
provides a time when (barring sleep apnea) there is continued effective ATP production from oxygen, but reduced 
energy expenditure through muscle, an aerobically demanding tissue. (Sleep deprivation also promotes oxidative 
stress416.) This is consistent, from the energy deficit perspective, with the finding that sleep restriction or loss 
promotes MetS. It also affords the possibility that impaired energetics and increased energy demand may 
(adaptively) promote longer sleep time. There is evidence in apparent support of this: conditions linked to increased 
energy demand and reduced energy supply are linked to increased sleepiness or prolonged sleep time171,417; and 
coenzyme Q10, which benefits mitochondrial function and cell energetics, reduced excessive sleep time (and 
excessive eating) in a condition in which prolonged sleep (and excessive eating) are a feature64. Additionally, while 
sleep restriction is linked to MetS and diabetes (and its consequences like CHD), long sleep duration is also linked 
to incident diabetes170 (and CHD418), with the reason for the latter recently deemed unclear170. Here it is proposed 
that short sleep duration drives inadequate energetics (creating a link to MetS); and that inadequate energetics drives 
increased sleep duration as an energy supporting adaptation–and also drives energy supportive MetS elements, 
producing the bidirectional association between sleep duration and MetS (this is testable in animal models, with 
some extant supportive evidence202). 
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Table 2. The “Starving Cell” Energetic Perspective Explains Many Findings 
Explains Comment, Clarification, or Example 
Why Diverse MetS Factors Cohere Why the apparently diverse MetS factors share many common risk and protective 
factors, commonly group together, and are linked to common outcomes. 
Why Other Energy Supportive 
Factors Cohere With MetS Factors 
Examples: Elevated free fatty acids186,295, ectopic fat deposition194,338 (free fatty acids 
and ectopic fat may be used for cell energy191), increased hunger or appetite 
sensations35,172,175,200, increased sleep duration170,202 are linked to MetS –see below, 
Bidirectional associations. 
Which Factors Promote and 
Retard MetS Factors 
Provides a unified framework that explains factors linked to increased and reduced 
risk - beyond calorie intake and exercise-related energy expenditure. See Table 1. 
(Accounts for why, for instance, fruit consumption, with antioxidant and 
micronutrient energy supportive effects– though high in “sugar”–is linked to lower 
risk of MetS419.) 
Why a Range of Other Markers 
are Linked to MetS a 
Markers linked to causes of energy deprivation, and other corollaries or 
consequences of those causes, show a relation to MetS, as expected in the energy 
deficit view. a 
Bidirectional Associations to MetS 
b
 
Both extremes for factors like sleep duration show associations to MetS. The 
Starving Cell hypothesis provides an explanation, with one direction (energy 
depleting–e.g. short sleep duration) as cause of MetS; the opposite direction (energy 
supportive –e.g. prolonged sleep duration) as concurrent adaptive consequence, 
together with MetS factors, of energy deficit. b 
Health Associations of MetS c 
 
Health effects (i.e. beyond cardiovascular disease) are linked to MetS such as cancer 
and depression and cognitive decline. An association of MetS to mitochondrial 
dysfunction, oxidative stress and energy impairment provides a explanation–via 
common cause - for these associations. c 
“Push Me, Pull You” Treatment 
Phenomena d 
When one MetS factor is targeted for treatment, others commonly worsen. If needed 
accessory energy support from one source is withdrawn, another source may be 
called upon. d  
Inverse Relations of MetS to Non-
Visceral Fat 
More ready access to energy from stored peripheral fat–greater fat cell number (vs. 
increased fat cell size), and greater vasculature in adipose tissue420–has been linked 
to lower risk of MetS. Where other energy sources are available to be drawn upon, 
the likelihood of energy deficit, and the need for the supplemental energy sources 
that comprise MetS, may be reduced.  
Seasonal Findings e BMI, triglycerides, and blood pressure rise in winter in association with low 
temperature (but not rainfall), consistent with the energy deficit (but not energy 
surfeit) view (lower temperature increases energy demand for thermogenesis). 
 Moreover the effects are greater in more energetically vulnerable persons including 
elderly. e 
Why MetS is also rising in poor 
nations; and among poor people in 
rich nations. 
Factors like environmental oxidative stressors (e.g. pesticides, herbicides, industrial 
products), nutrient-impoverished foods, access to carbohydrate predominant foods 
and those with prooxidant ingredients (e.g. trans fats, artificial ingredients) would, 
under the energy deficit perspective, be predicted to have this effect. Indeed greater 
exposures to oxidative stressors, associated with lower socioeconomic state, may 
contribute to findings that antioxidant rich diets showed a significantly larger benefit 
to blood pressure in minority relative to nonminority groups, p < 0.00182. 
Why Treatment of MetS Factors 
Fully to “Normal” Is Commonly 
Not Beneficial (relative to 
treatment partway to normal) 
Unless by means that address energy/ oxidative stress, treatments of MetS factors 
that push them fully to the “normal” range have often  been neutral or even 
unfavorable relative to partial correction (for lipids272, glucose271, blood pressure273, 
weight274)–and particularly so in settings of impaired energy supply (older elderly) 
and/or increased demand (illness, injury, surgery) 
Why MetS Factors Increase with 
Age 
Mitochondrial deficits increase with age383 promoting cell energy deficits. 
Endothelial dysfunction421 and, according to some studies, oxidative stress do as 
well422. Atherosclerotic blockage of vessels itself rises with age, restricting cell 
access to substrates and nutrients needed for energy production. Each of these would 
predict rise in MetS factors with age under the energy deficit perspective. 
Why MetS Factors “Paradoxically” 
Predict Better Rather than Worse 
Subjects who are overweight or even obese are reported to have “paradoxically” 
lower complication rates and mortality than those who are underweight or normal 
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Outcomes–in Older Elderly and 
Other Settings of Impaired Energy 
Supply and Reduced Energy 
Demand f 
weight among older elderly256,257 among persons with heart failure (impairing 
oxygen delivery)258,259, cardiovascular disease (impairing oxygen delivery)264, 
chronic kidney disease (impairing oxygen delivery–via effects on erythropoietin for 
instance)265, undergoing dialysis266, percutaneous coronary interventions267,268 and 
nonbariatric surgery269 (high energy demand) and in persons with AIDs or cancer 
(settings of increased energy demand) 266p Similar “paradoxes” are observed in such 
settings for lipids257,266,270 and blood pressure266.  
Why Correction of MetS Factors to 
Targets Defined in Younger 
Healthy Subjects May Lose Benefit 
in Older Elderly–and Other 
Settings of Energy Vulnerability 
Unless by means that address energy/ oxidative stress.  See footnote “f” to Table 1. 
Coheres with Previously ~Accepted 
Adaptive Findings 
E.g. findings suggesting adaptive mechanisms from energy deprivations in prior 
generations (Thrifty Gene), or in fetal life, are linked to increased risk of MetS. 
Converts Risk Factors from 
Paradoxical to Expected 
Risk factors that are “paradoxical” in the energy surfeit view emerge naturally from 
the deficit perspective. 
Reconciles Conflicting Perspectives Such as whether MetS should be viewed from a glucocentric or lipocentric view194. 
The answer: neither and both–rather an energy-centric view is appropriate. 
 
a. Other markers that have been linked to MetS relate to (A). Factors that promote energy impairment, e.g. 
markers of oxidative stress213; poor micronutrient status118,120, or hypermetabolic state210,423 which may 
thus serve to promote MetS. (B). Markers related to consequences of the factors in (A): E.g. oxidative 
stress sequelae: antioxidant adaptations (e.g. elevated GGT213,225 and uric acid222,223); endothelial 
dysfunction93; and activated inflammation and coagulation pathways (e.g. CRP210-213, fibrinogen210). 
Oxidative stress promotes apoptosis206,424-426–which triggers coagulation and inflammation208. (C) Markers 
related to cell energy preserving adaptations.  
b. Accounts for some apparently paradoxically bidirectional associations to MetS. Some factors are linked to 
MetS as a cause (calorie deficit, low antioxidant levels, high metabolic rate, short sleep duration–which by 
hypothesis promote MetS by promoting energy deficit); while their inverse may linked to MetS as an 
adaptive consequence (high calorie intake, high antioxidant levels, low resting metabolic rate, prolonged 
sleep are by hypothesis adaptive consequences of energy deficit, together with MetS). Of note, the 
directionality proposed is testable in animal models.  
c. Provides an alternate explanation for many associations of MetS to adverse outcomes such as cancer229,427, 
cognitive decline428, depression231,429, fibromyalgia230,430, as well as all-cause mortality431. Associations 
may be driven substantially by common cause: Cell energy deficit, oxidative stress, mitochondrial 
dysfunction (or their causes or sequelae) may concurrently increase risk of MetS and the other outcomes. 
(Note: many of the somatic symptoms that count toward depression are symptoms of cell energy 
impairment227.) 
d. Explains what might be termed a “Push me, Pull you” phenomenon: Viewed from the energy surfeit 
perspective, interventions that reduce one MetS factor should be neutral if not favorable to other MetS 
factors. Instead, pushing down one MetS factor commonly leads another MetS factor (or energy 
adaptation) to be expressed. s: Severe calorie restriction (despite short term weight loss) worsens IR/ MetS 
factors151. Insulin and sulfonylurea treatments to reduce glucose often lead to weight gain243,432. Niacin, 
statins, and/or fibrates to benefit lipid elements of MetS worsen insulin sensitivity433; promote glucose 
elevation233-237,434, and (fibrates) increase free fatty acids433. Larger lipid reductions on statins are linked to 
weight gain 435 as are higher dose statins436. Thiazides, beta blockers and salt restriction (to lower blood 
pressure) promote dyslipidemia239,241,437 and (at least for thiazides) glucose intolerance/diabetes242♦. 
                                                 
♦
  ACE inhibitors increase mitochondrial Q10 content438. Gvozdjakova A, Simko F, Kucharska J, Braunova Z, Psenek P, 
Kyselovic J. Captopril increased mitochondrial coenzyme Q10 level, improved respiratory chain function and energy production in the 
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Treatments seeking to target blood pressure and dyslipidemia can also, in some people, paradoxically 
adversely effect the same MetS element they are intended to benefit275-277,439-441° (and efforts to lower 
weight can lead to weight regain). These findings are unexpected in the energy surfeit view, but 
predictable if the MetS element being “corrected” was serving adaptive energy supportive functions that 
must now be accommodated another way. This “push me, pull you” effect does not occur for interventions 
that improve MetS by supporting energy (CPAP for sleep apnea; coenzyme Q10, hypoglycemia 
preventive/nutrient preserving diet), which tend to benefit most or all MetS elements in tandem.  
e. MetS factors rise in winter. This has been shown for BMI442 (and moreso fat mass443), triglycerides and 
cholesterol444-446, and blood pressure164-167,447,448. Winter rises in BP have been shown to relate 
significantly to daily temperature specifically164,165 (indeed associations are reportedly extinguished with 
adjustment for temperature164) - but not for instance to relate to rainfall166,167, militating against an 
explanation founded on lack of access to outdoor exercise. The BP change is reportedly greater in 
underweight than normal and overweight persons; and greater in older subjects for both BP166 and lipids445 
- groups with lesser weight buffering for energy; and more mitochondrial impairment respectively. 
Seasonal BP changes are greater in hypertensives167 while seasonal lipid changes are greater in those with 
high cholesterol446–reinforcing that both the initial defect and its seasonal aggravation may have a 
foundation in energetic adaptation. 
f. Additionally, in poststroke patients (in whom affected and neighboring brain regions have high energetic 
vulnerability and may be particularly perfusion dependent449,450), blood pressure often rises451,452. 
Reducing blood pressure to normal (unless by means that improve perfusion/energy) may worsen 
outcomes in this setting453. The detriment is greater in energetically vulnerable persons such as elderly454. 
Indeed, blood pressure raising therapy may improve outcomes39,455,456. 
 
 
                                                                                                                                                                                     
left ventricle in rabbits with smoke mitochondrial cardiomyopathy. Biofactors. 1999;10(1):61-65. and evidently do not have this 
effect. 
°
 Severe calorie restriction could, in a way, be viewed in this light, driving adaptive mechanisms that may lead to weight gain – if often 
not immediately. 
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Table 3. The “Starving Cell” Energetic Perspective Provides Predictions and Implications:  
A number of predictions are contrary to current thinking and practice. 
Interventions intended to benefit MetS 
elements, that unfavorably affect cell 
energy, may adversely affect MetS in 
long term 
For instance, efforts targeting children to promote nonfat and 1% milk 
over 2% and whole milk will promote MetS rather than protect against it: 
Nonfat/lowfat milk are expected to lead to less favorable effects on 
insulin (less fat to buffer the glycemic rise with lactose); and lesser 
benefits to vitamin D (which requires fat to be assimilated and is 
important for energetics)–as well as, incidentally, promoting more 
apparent lactose intolerance457. More generally, low fat diets (by 
mechanisms above, promoting carbohydrate-induced glucose drops), 
severely calorie restricted diets, and diets that restrict calories without 
supporting micronutrient and antioxidant functions of food, will promote 
MetS. Low salt diets, by reducing blood volume and perfusion of 
relatively hypoperfused tissues, will promote MetS in the long term. Of 
note, effective intentional weight loss has been linked to higher 
mortality274. 
Diets that focus on preserving cell energy 
will yield less MetS, better long term 
weight status, and better outcomes 
Dietary efforts that focus on micronutrient dense “real” foods, avoidance 
of fasting, regular meals with macronutrient balance (no restriction on 
high quality fats - excludes artificial trans fats e.g.), inclusion of fat and 
protein in meals, ample dietary vitamin D, E, and A - and ensuring 
vitamin D adequacy specifically), limitation of nutrient impoverished 
simple carbohydrates (though more carbohydrates are needed with 
exercise), and avoidance of foods containing artificial ingredients, and 
focused on antioxidant rich foods will promote long term weight loss 
more than efforts to restrict calories and/or fat–and lead to better hard 
outcomes. 
Oxidative stressor exposures will 
increase MetS 
Persons with significant exposure to oxidative stressors (e.g. repeated 
exposure to pesticides/herbicides or heavy metals) will be at increased 
risk for MetS on average. (Caution: Those with adverse oxidation 
profiles may react more adversely and self-select away from high 
exposure settings.) 
For bidirectional associations to MetS: 
Animal studies will support cause-
consequence predictions. 
Bidirectional association of energy-associated factors to MetS–like 
antioxidant state, and sleep duration–will be demonstrated (for instance 
in animal studies) to relate to cause and consequence of energy 
impairment. E.g. adverse antioxidant/prooxidant state and sleep 
restriction promote MetS; while prooxidant exposures and energy 
depletion (with which MetS is associated) will promote adaptive 
increases in antioxidant levels and sleep duration (respectively). Calorie 
intake can be viewed in this way as well–marked calorie restriction 
promotes MetS151 and MetS/associated energetic impairment drives 
calorie intake. (Such bidirectional associations must be recognized as 
they can complicate observational studies. Intervention studies are 
needed to understand directionality/causality.) 
Multifaceted support of cell energy in 
ill/injured hospitalized patients (high 
energy demand) will reduce MetS and 
improve outcomes. 
In hospitalized patients under high energy demand (serious illness, 
trauma, surgery), concerted efforts to support cell energy will reduce 
MetS factor promotion that arises in these settings–and will also improve 
outcomes extending to mortality. Measures to support energy include: 
ensuring a warm environment, provision of supplemental oxygen, good 
light exposure during the day (and little at night), avoidance of relative 
hypotension or hypoglycemia, avoidance of fasting/missed meals, 
regular meals and snacks high in quality and adequate in quantity for 
those able to eat (not low fat), limiting blood loss from blood draws, 
avoidance of sleep disruption/restriction∇, and treatment of sleep apnea if 
                                                 
∇
 Consistent with energetic demands of healing, sleep restriction has been shown to retard wound healing458. Gumustekin K, 
Seven B, Karabulut N, et al. Effects of sleep deprivation, nicotine, and selenium on wound healing in rats. Int J Neurosci. Nov 
2004;114(11):1433-1442.. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
53
5.
1 
: P
os
te
d 
15
 O
ct
 2
01
1
present (with consideration of routine testing for this highly prevalent 
condition). Energetic and antioxidant support via a high quality 
coenzyme Q10 supplement, and support of vitamin D if deficiency/ 
insufficiency is present, may merit testing. Many of these–related to 
feeding, phlebotomy, and sleep–are in conflict with current hospital 
procedures.  
Support of cell energy in pregnant 
patients will reduce preeclampsia and 
gestational diabetes. 
Similarly, interventions to support cell energy and reduce oxidative 
stress will reduce risk of preeclampsia and gestational diabetes in at-risk 
pregnant women. 
Animal studies (properly done) will 
support the energy deficit over the 
energy surfeit hypothesis 
The hypothesis predicts that high calorie diets–presumed in and of 
themselves to cause MetS in the energy surfeit model–when energy 
deficit is prevented (the diet is nutritionally rich, ample in the spectrum 
of beneficial antioxidants, and with macronutrient composition 
supporting cell energy - adequate in high quality protein and fat)–will be 
associated with lower risk of MetS than diets (calorie neutral, calorie 
restricted or calorie replete) in which cell energy deficit is enabled. 
Factors promoting impaired energetics 
will be found to promote sleep apnea 
Energy is involved in muscle function which is required for airway tone, 
contributing to airway caliber and protection against airway muscle 
fatigue and airway collapsibility–involved in sleep apnea (which in turn 
impairs oxygenation and energetics). (Thus, sleep apnea is common in 
postpolio syndrome459.) Thus, secular trends that promote the rise in 
MetS may concurrently promote secular increases in sleep apnea–not 
solely through obesity. (CPAP–which improves oxygen and energy–
improves airway caliber and reduces collapsibility in sleep apnea319; 
analogously it is proposed that factors that impair cell energetics reduce 
airway caliber and increase collapsibility.) 
Reputed benefits of “calorie restriction” 
in rodent and primate studies will be 
attenuated (and possibly obviated) when 
the comparator diets are matched in 
macronutrient and 
micronutrient/antioxidant composition; 
and when energetic stressors are 
introduced.  
Ironically, calorie restricted diets in the animal studies that support life 
prolongation are designed to preserve cell energy. Currently in these 
studies calorie restricted diet groups receive a diet that is higher in fat, 
more nutrient-dense, and more antioxidant promoting, features that 
benefit MetS elements and cell energy irrespective of calorie 
composition83,155,460 and benefiting all-cause mortality (survival) relative 
to more nutrient impoverished, carbohydrate-rich, more prooxidant diets 
of rat chow and monkey chow used in the control animals461. Calorie 
restriction without the favorable dietary modification leads to animal 
death. The remaining necessary control–incorporating the macronutrient 
and micronutrient benefits of the calorie restricted diets in the higher 
calorie diets–has not been done. Nor have studies incorporating “real-
world” energetic stressors, such as infection, trauma, and chemical/ 
oxidative stressor exposure. 
Transgenerational effects may be 
expected.  
Energy deprivation to a fetus (including through restricted calories in the 
mother) is recognized to influence risk of MetS-related factors and other 
energetic adaptations32 in later life. It is predicted that many of the other 
sources of energy depletion reviewed here (as well as older maternal age, 
linked to mitochondrial dysfunction and energy depletion) may adversely 
affect energy to the fetus (with or without evidence of growth retardation 
or macrosomia), disposing to MetS factors in childhood and later life. 
Exposure of a pregnant woman to oxidative stressors and mitochondrial 
toxins might influence her female offspring’s germ line (all eggs develop 
while in utero), creating potential risks two generations down and in the 
germ line. MetS factor development in offspring may produce oxidative 
stress (e.g. glycation products) and energetic deficits which may extend 
effects to offsprings’ offspring. 
Societal efforts aimed at curbing 
environmental oxidative stressor 
exposures will be central to arresting the 
epidemic of MetS and obesity.  
Oxidative stressors have increased dramatically in recent decades, and 
are currently omnipresent, in household products (cleaning products, air 
fresheners, fabric softeners), personal care products, furnishings and 
fabric treatments (particle board/formaldehyde313, new carpeting, 
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fireproofing materials), yard/ landscaping products (pesticides300,356, 
herbicides462-464), petroleum products311, pollutants465 and contaminants 
in air466, water467-471, and foods/ beverages472-474. Discretionary (as well 
as more necessary) over-the-counter and prescription medications303-
305,475-482
, electromagnetic radiation including from cell phones and 
towers308,309,483, modified food ingredients306,307,369 and food 
containers373,374,376,377, sleep deprivation484,485–and drugs in the water 
supply467 promote oxidative stress. Exposures are determined not only by 
an individual’s use of these products, but by products used at their 
workplace; and by use of pesticides/herbicides by landscapers for public 
areas (parks) and neighbors (for those who walk or play in their 
neighborhood). Analogous to the case of second hand smoke, more 
regulation of products and exposures that affect others’ exposure could 
particularly be considered. 
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